The clinical usefulness of @entity3508 ( @entity3508 ), @entity1014 kinase (TK), and @entity3145 ( @entity3145 ) was investigated in 41 @entity1 (53-80 years old) with recently discovered @entity151 ( @entity151 ). Eleven @entity1 exhibited @entity66 ( @entity66 ) and 30 @entity66 ( @entity66 ). Serum samples for @entity3508 , @entity3145 (immunoradiometric assay), and TK (radioenzymatic assay) evaluations were drawn from all @entity1 at the time of diagnosis and before each cycle of chemotherapy in the treated @entity1 . Therapy consisted of i.v. @entity3003 300 mg/m2 on the first day and i.v. @entity2879 120 mg/m2 from the first to the third day every 3 weeks. Nine @entity1 refused or were not eligible for chemotherapy. Five @entity1 received only one course and showed no response (NR); 9 @entity1 received two courses; 18 @entity1 received three or more courses. In the last group, complete remission (CR) was obtained in 9 cases, partial remission (PR) in 18 cases. The @entity5 markers studied did not show any significant difference in distinguishing @entity66 from @entity66 . @entity3508 and @entity3145 were significantly more often abnormal than TK, either at the time of diagnosis (p < 0.05) or in PR or NR @entity1 (p < 0.05). In relation to chemotherapy response, @entity3508 and @entity3145 serum patterns were shown to be more reliable than TK in PR (p < 0.05) and NR @entity1 (computed error between 10% and 15%). No significant difference was observed between serum @entity3508 and @entity3145 patterns. Serum @entity3508 and @entity3145 seem to be more useful in the diagnosis and follow-up of @entity151 @entity1 undergoing chemotherapy. Further trials are necessary to ascertain whether the associated assessment of @entity3508 and @entity3145 can add useful information to that provided by the assessment of @entity3508 alone.

@entity3508 , XXXX kinase, and @entity3145 in diagnosis and response to chemotherapy of @entity151 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['extensive disease', 'limited disease', 'LD', 'ED'] @entity3145 :: ('MESH:D017695', 'Disease') :: ['tissue polypeptide-specific antigen', 'TPS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity3508 :: ('2026', 'Gene') :: ['NSE', 'neuron-specific enolase'] @entity1014 :: ('MESH:D013936', 'Chemical') :: ['thymidine'] @entity151 :: ('MESH:D055752', 'Disease') :: ['SCLC', 'small-cell lung cancer']
@entity1014 :: (MESH:D013936,Chemical) :: ['thymidine']
